Reports on gastric cancer therapy findings from Institute for Clinical Research provide new insights
2008 JAN 17 -- New investigation results, 'Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients,' are detailed in a study published in Cancer Chemotherapy and Pharmacology. Researchers in Fukuoka, Japan conducted a study "To evaluate the comprehensive safety profile of S-1, a promising novel oral fluoropyrimidine derivative, based on large cohort data. Study subjects were identified from a prospective registry of 3,758 advanced gastric cancer patients in Japan." "Each patient was treated with an identical regimen of S-1 monotherapy (40 mg b.i.d. on days 1-28, every 6 weeks) and assessed for all adverse events. The median duration of treatment was 88 days; 1,605 (43%) patients underwent three or more treatment cycles. The relative dose intensity was 0.87 in the first two cycles (short-term treatment period) and 0.89 thereafter (long-term treatment period). Neutropenia was the most common severe (grade 3-4) hematological event (6.3% in the short-term period and 5.3% in the long-term period). Other hematological or key gastrointestinal events (diarrhea, nausea/vomiting, and stomatitis) had a low incidence of severe cases throughout the whole administration period (0.3-3.8%). The time to onset of severe events did not differ between patients with mild renal impairment (creatinine clearance, 50-79 ml/min) and those with normal renal function (>or=80 ml/min) (hazard ratio, 1.04; 95% CI, 0.87-1.23; p=0.691). S-1 had manageable severe toxicity and allowed good compliance regardless of treatment duration," wrote T. Yamanaka and colleagues, Institute for Clinical Research. The researchers concluded: "Prolonged administration of the drug was sustainable." Yamanaka and colleagues published the results of their research in Cancer Chemotherapy and Pharmacology (Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients. Cancer Chemotherapy and Pharmacology, 2008;61(2):335-43). For additional information, contact T. Yamanaka, Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan. The publisher of the journal Cancer Chemotherapy and Pharmacology can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. Keywords: Japan, Fukuoka, Gastric Cancer Therapy, Adverse Drug Effect, Adverse Drug Event, Adverse Drug Reaction, Chemotherapy, Clinical Research, Drug Development, Drug Therapy, Drugs, Gastric Cancer, Gastric Carcinoma, Hematology, Neutropenia, Oncology, Pharmaceuticals, Pharmacology, Therapies, Therapy, Treatment. This article was prepared by Blood Weekly editors from staff and other reports. Copyright 2008, Blood Weekly via NewsRx.com.
|
